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Abstract
Monocytosis is associated with chronic infections such as tuberculosis or endocarditis as well as rheumatic and myeloproliferative
disorders. Monocytes are also involved in the pathogenesis of atherosclerosis, coronary artery disease, and stroke. The value of
monocytosis as a prognostic marker in different diagnostic groups in the emergency setting, however, has not been investigated so
far.
The aim of the article is to study monocytosis as an outcome factor in the emergency setting.
In a Swiss register study, we analyzed monocyte counts in 4238 patients aged >18 years who were admitted to the emergency
department of a regional tertiary care hospital. Monocytosis was deﬁned as 0.8109cells/L. Diagnoses were grouped into infection,
cardiovascular, neurological, metabolic, gastrointestinal, pulmonary, or other. Thirty-day mortality was deﬁned as the primary
endpoint
A total of 1217 patients with monocytosis were identiﬁed. Patients with monocytosis at admission suffered more frequently from
respiratory symptoms (17.7% vs 8.9%, P<.001) and infection as the ﬁnal diagnosis (20.8% vs 10.3%, P<.001) while neurological
diagnoses were signiﬁcantly lower in the monocytosis group (15.3% vs 30.9%, P<.001). Patients with monocytosis suffered from
more comorbidities such as congestive heart failure, chronic obstructive pulmonary disease, tumor, diabetes, or renal failure but not
dementia. When adjusted for age, gender, comorbidities, and main diagnosis, the 30-day mortality (P= .002) and length of stay
(P= .001) were signiﬁcantly higher in patients with monocytosis. The 30-day mortality in patients with monocytosis was most notably
inﬂuenced by a cardiological diagnosis (odds ratio 3.91).
An increased monocyte count predicts adverse outcome in patients admitted to the emergency department. Mechanistic studies
will be necessary to specify the potentially detrimental role of monocytosis in critical illness.
Abbreviations: AMI = acute myocardial infarction, CAD = coronary artery disease, CHF = congestive heart failure, CI =
conﬁdence interval, COPD = chronic obstructive pulmonary disease, CRP = C-reactive protein, ED = emergency department, HR =
hazard ratio, ICU = intensive care unit, IQR = interquartile range, NRS = nutritional risk score, OR = odds ratio, WBC = white blood
cell.
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1. Introduction involved in cytokine expression, antigen presentation, orMonocytes represent about 5% of all leukocytes in the peripheral
blood.[1] After circulating for several days in the bloodstream,
monocytes usually undergo extravasation. In the tissue they
differentiate into macrophages or dendritic cells[2] and areEditor: Ken S. Rosenthal.
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1phagocytosis.[3] “Patrolling” monocytes constantly migrate
along the endothelium in blood vessels serving as vascular
innate immune system.[4] Monocytes can be speciﬁed into
different subsets such as CD16high14monocytes which produce
high amounts of inﬂammatory cytokines such as tumor necrosis
factor or a more regulatory CD16low14+ monocyte subset.[5,6]
As widely known monocytosis occurs in chronic infection
such as tuberculosis, endocarditis, granulomatous disease,
or in myeloproliferative disorders. Other disorders that can be
associated with increased monocyte counts are the metabolic
syndrome[7] and autoimmune disorders including rheumatoid
arthritis.[8] The underlying pathophysiology leading to mono-
cytosis is not fully understood. Chemokines such as monocyte
chemoattractant protein-1 and growth factors trigger monocyte
recruitment and homeostasis.[9] Smoking also leads to increased
monocyte numbers.[10]
Monocytosis is associated with artherosclerosis and its
consequences such as coronary artery disease, cerebrovascular
disease, or kidney artery stenosis, for example, as a source of foam
cells.[11,12] Increased monocyte counts after acute myocardial
infarction (AMI)were associatedwith left ventricular dysfunction,
left ventricular aneurysm, and other cardiac events.[13] Another
study showed similar effects to the nonrecovery of the left
[14]
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monocytosis has been identiﬁed as an independent risk factor
for myocardial infarction or cerebral arterial disease.[15] The level
of the National Institutes of Health Stroke Scale on stroke patients
correlates with the amount of monocytes.[16]
So far, the prognostic value of monocytosis in the emergency
setting has not been investigated although monocyte numbers
usually are assessed in routine blood tests. In this Swiss register
study we have analyzed monocytes counts in patients admitted to
the emergency department as a predictive factor for survival and
hospital stay.2. Methods
2.1. Study design and setting
This is an observational, prospective cohort study. Between
March 2013 and February 2014, consecutive adult medical
patients were included upon hospital admission in the emergency
department into the quality-control TRIAGE project. This
project’s main aim is to optimize the triage and patient ﬂow of
adult patients with medical emergency.[17]
As an observational quality control study, the Institutional
Review Board (IRB) of the Canton of Aargau has approved the
study and waived the need for informed consent (EK 2012/059).
2.2. Patient population and management
Adult in-patients with an acute medical illness were included in
this study; children and surgical patients were excluded. We
collected pertinent clinical information, including sociodemo-
graphic characteristics, main medical diagnosis, and comorbid-
ities at hospital admission using the information routinely
gathered from the hospital electronic medical system for coding
of diagnosis-related group codes. This already available
information supported the reliable assessment of baseline
characteristics and different patient outcomes. Clinical informa-
tion and patient outcomes were assessed until hospital discharge
and structured patient interviews were conducted via telephone
30 days after hospital admission to assess information about
different clinical and functional outcome measures such as
location after discharge, quality of life, performance of activities
of daily living, hospital readmission, and mortality. If a patient
could not be reached, we contacted the family or the general
practitioner to assess vital status.2.3. Main diagnosis and comorbidities
Patients were divided into main diagnosis groups including
infections, cardiovascular diseases, metabolic diseases, cancer,
neurological disorders, digestive tract diseases, pulmonary
diseases, and other disease. We also deﬁned the following
comorbidity groups: congestive heart failure, chronic obstructive
pulmonary disease (COPD), dementia, diabetes mellitus, tumor,
renal failure, and obesity.2.4. Outcomes
Our primary outcomes were 30-day mortality, in-hospital
mortality, length of stay, intensive care unit (ICU) admission,
and rate of 30-day readmission assessed during the hospital stay
and by telephone interviews at day 30.
Secondary outcomes included functional impairment and
quality of life. Performance of daily living was measured by2the Barthel index. We deﬁned functional impairment as a Barthel
index<95 points. In order to assess quality of life, we used the
standardized measure of health EQ-5D including a descriptive
system with 5 dimensions (mobility, self-care, usual activities,
pain/discomfort, anxiety/depression). These results were dis-
played as 2 levels, “impairments” or “no impairments.”2.5. Assessment of monocyte count and deﬁnition
of monocytosis
Monocytes were counted using the automated hematology
analyzer Sysmex XN or by hand in case of discrepancy. The
Sysmes XN uses ﬂuorescence and the SAFLAS method (Sysmes
adaptive Flagging Algorithm based on Shape-recognition) for
monocyte recognition.
The cut off for monocytosis was deﬁned as 0.8  109/L blood,
which is according to common literature. Monocytopenia was
deﬁned as 0.3  109 cells/L blood. Both thresholds were tested in
this cohort regarding the 30-day mortality.2.6. Statistical analysis
Categorical variables are expressed as percentages and counts or
vice versa and continuous variables as medians (interquartile
ranges: 25th–75th percentiles), unless stated otherwise. Frequen-
cy comparison was done by the x2 test. For all binary endpoints,
logistic models with odds ratios (OR) and 95% conﬁdence
intervals (95%CI) were used. For time to hospital discharge, Cox
regression models with hazard ratios (HR) were calculated. To
adjust for possible confounds, we used 3 statistical models: model
1 for age and gender; model 2 for age, gender, and comorbidities;
and model 3 for age, gender, comorbidities, and main diagnosis.
We evaluated the association between monocyte count and
outcomes in the overall population as well as within different
predeﬁned subgroups based on gender, age (cut off 75 years) and
main medical diagnosis. Evidence of effect modiﬁcation within
these subgroups was assessed by including interaction terms into
the statistical models. A P value <.05 (for a 2-sided test) was
considered statistically signiﬁcant. All statistical analyses were
performed with STATA 12.1 (Stata Corp, College Station, TX).3. Results
3.1. Patient characteristics and comorbidities
The mean age in patients with monocytosis was higher compared
to patients with normal monocyte counts (66 vs 61 years,
P<.001, Table 1) and there were more male patients in the
monocytosis group (65.7% vs 51.4%, P<.001). The nutritional
risk status was higher in patients with monocytosis (P= .001)
and accordingly, patients with monocytosis had lower albumin
values (P= .001). Serum creatinine (P= .001), CRP (P= .001),
and blood leukocyte count were also higher in the monocytosis
group (P= .001). Diabetes (P= .002), tumor (P<.001), heart
failure (P= .022), COPD (P<.001), renal failure (P<.001), and
obesity (P<.001) were more prevalent in patients with mono-
cytosis. Conversely, dementia was not more frequently observed
in monocytosis (P= .086).
3.2. Symptoms and diagnosis
At admission, neurological symptoms (16.4% vs 29.7%,
P<.001) and thoracic pain (14.9% vs 16.9%, P<.001) were
lower in the monocytosis group whereas respiratory symptoms
Table 1
Patient characteristics overall and according to monocyte count (counts per liter blood stated).
Overall 0.3–0.8109/L >0.8109/L
P valuen 4238 2708 1217
Age, median (IQR) 63 (46, 75) 61 (44, 75) 66 (50, 77) <.001
Female gender, n (%) 1888 (44.6%) 1315 (48.6%) 418 (34.3%) <.001
Male gender, n (%) 2350 (55.4%) 1393 (51.4%) 799 (65.7%) <.001
NRS <3, n (%) 1165 (27.5%) 678 (25.0%) 400 (32.9%) <.001
NRS ≥3, n (%) 375 (8.9%) 186 (6.9%) 128 (10.5%)
NRS not assessed, n (%) 2698 (63.7%) 1844 (68.1%) 689 (56.6%)
Initial blood biomarkers, median (IQR)
Albumin, g/L 37.7 (34, 40.7) 38.4 (35.3, 41.0) 36.4 (32.1, 39.7) <.001
Creatinine, mmol/L 85 (70, 105) 82 (68, 100) 91 (76, 116) <.001
Calcium, mmol/L 2.26 (2.19, 2.35) 2.25 (2.18, 2.33) 2.29 (2.21, 2.39) <.001
CRP, mg/L 17.9 (6.9, 68.9) 12 (6, 36) 34 (10, 110) <.001
WBC, g/L 8.5 (6.7, 11.0) 7.8 (6.4, 9.4) 11.5 (9.3, 14.2) <.001
Location after hospital/ED discharge, n (%)
Home 1635 (38.6%) 998 (36.9%) 513 (42.2%) .006
Other hospital 224 (5.3%) 151 (5.6%) 59 (4.8%) .51
Nursing home 172 (4.1%) 107 (4.0%) 48 (3.9%) .44
Rehabilitation clinic 197 (4.7%) 120 (4.4%) 58 (4.8%) .42
Other or unknown 1897 (44.8%) 1283 (47.4%) 499 (41.0%) <.001
In-hospital death 113 (2.7%) 49 (1.8%) 40 (3.3%) <.001
Comorbidities, n (%)
Diabetes 609 (14.4%) 357 (13.2%) 211 (17.3%) .002
Tumor 630 (14.9%) 315 (11.6%) 200 (16.4%) <.001
Congestive heart failure 250 (5.9%) 140 (5.2%) 90 (7.4%) .022
COPD 204 (4.8) 107 (4.0%) 83 (6.8%) <.001
Dementia 130 (3.1%) 84 (3.1%) 38 (3.1%) .86
Renal failure 630 (14.9%) 344 (12.7%) 229 (18.8%) <.001
Obesity 518 (12.2) 313 (11.6%) 181 (14.9%) <.001
Main diagnosis, n (%)
Infection 604 (14.3%) 278 (10.3%) 253 (20.8%) <.001
Cardiovascular 944 (22.3%) 637 (23.5%) 272 (22.4%) <.001
Metabolic 59 (1.4%) 35 (1.3%) 21 (1.7%) .45
Cancer 213 (5.0%) 90 (3.3%) 68 (5.6%) <.001
Neurological 1080 (25.5%) 838 (30.9%) 186 (15.3%) <.001
Gastrointestinal 457 (10.8%) 250 (9.2%) 167 (13.7%) <.001
Pulmonary 157 (3.7%) 78 (2.9%) 70 (5.8%) <.001
Other 724 (17.1%) 502 (18.5%) 180 (14.8%) .003
Main symptom at ED admission, n (%)
Fever 237 (5.6%) 103 (3.8%) 89 (7.3%) <.001
Diarrhea, vomitus, dysuria 265 (6.3%) 138 (5.1%) 92 (7.6%) <.001
Nonthoracic pain 641 (15.1%) 413 (15.3%) 173 (14.2%) .32
Thoracic pain 659 (15.6%) 457 (16.9%) 181 (14.9%) <.001
Neurological symptoms 1060 (25.0%) 804 (29.7%) 199 (16.4%) <.001
Respiratory symptoms 487 (11.5%) 240 (8.9%) 215 (17.7%) <.001
Worsening of general condition 232 (5.5%) 116 (4.3%) 89 (7.3%) <.001
Gastrointestinal bleeding 101 (2.4%) 64 (2.4%) 32 (2.6%) .56
Other symptom 556 (13.1%) 373 (13.8%) 147 (12.1%) .24
COPD= chronic obstructive pulmonary disease, CRP=C-reactive protein, ED= emergency department, IQR= interquartile range, NRS=nutritional risk score, WBC=white blood cell.
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(14.2% vs 15.3%, P= .32) pain was similar. Worsening of the
general condition (7.3% vs 4.3%, P<.001) and fever (7.3% vs
3.8%, P<.001) were also more likely in the monocytosis group.
In terms of diagnosis which let to hospital admission, neurologic
disorders were identiﬁed in 15.3% versus 30.9% (P<.001) of the
cases. Cardiovascular diagnosis as a reason for admission was
similar in monocytosis in 22.4% versus 23.5% (P <.001) in
patients with a normalmonocyte count. Themost notable increase
was observed in the diagnosis of infection (20.8% vs 10.3%,
P<.001). Gastrointestinal (13.7% vs 9.2%, P<.001), pulmonary
(5.8% vs 2.9%, P<.001), or cancer (5.6% vs 3.3%, P<.001)
diagnosis were higher in the monocytosis group.33.3. Mortality, length of hospitalization and functional
impairment
We studied mortality and length of hospitalization in different
models (Table 2). Adjusted for age and gender, 30-day mortality
(P<.001), length of stay (P<.001), and ICU admission (P= .020)
were signiﬁcantly higher in patients with monocytosis while in-
hospital mortality (P= .088) and rate of 30-day admission
(P= .100) were similar. When adjusted for age, gender,
comorbidities, and main diagnosis, 30-day mortality (P= .002)
and length of stay (P= .001) remained signiﬁcant. In a subgroup
analysis, the 30-day mortality was mostly inﬂuenced by
cardiologic diagnosis (OR 3.91, Table 3) but without a signiﬁcant
effect modiﬁcation. Conversely, there were no differences of
Table 2
Primary outcomes baseline overall and according to monocyte count.
Overall
Monocytosis
> 0.8109/L Unadjusted OR /
HR (95%CI), P value Model 1 Model 2 Model 3n 4238 1217
30-day mortality, n (%) 218 (5.1%) 90 (7.4%) 2.24 (1.66–3.02), <.001 1.85 (1.36–2.52), <.001 1.71 (1.25–2.35), .001 1.69 (1.22–2.35), .002
In-hospital mortality, n (%) 113 (2.8%) 40 (3.3%) 1.84 (1.20–2.81), .005 1.46 (0.95–2.24), .088 1.31 (0.84–2.04), .232 1.25 (0.79–1.98), .330
Length of stay (median, IQR) 3 (1, 7) 4 (1, 7) 0.86 (0.79–0.94), .001 0.86 (0.79–0.94), .001 0.88 (0.80–0 .96), .004 0.85 (0.78–0.93), .001
ICU admission, n (%) 166 (3.9%) 60 (4.9%) 1.62 (1.15–2.27), .005 1.51 (1.07–2.11), .020 1.44 (1.02–2.03), .040 1.40 (0.99–1.99), .060
Readmission, n (%)
No 30-day readmission 3406 (80.4%) 957 (78.6%)
30-day readmission 414 (9.8%) 129 (10.6%) 1.21 (0 .96–1.52), .095) 1.21 (0.96–1.52),.100) 1.18 (0.94–1.49), .157 1.22 (0.96–1.54), .100
30-day readmission not assessed 418 (9.9%) 131 (10.8%)
OR/HR for primary outcomes in patients with a monocyte count>0.8109/L compared to patients with a normal monocyte count. Adjusted for age /gender (Model 1), age/gender/comorbidities (Model 2), and
age/gender/comorbidities/main diagnosis (Model 3).
CI= conﬁdence interval, HR=hazard ratio, ICU= intensive care unit, IQR= interquartile range, OR= odds ratio.
Table 3
Subgroup analysis.
Outcome Monocytosis >0.8109/L OR (95% CI), P value P value for effect modiﬁcation
30-day mortality Overall 2.24 (1.66–3.02), <.001
Age .991
Age >75 2.11 (1.40–3.18), <.001
Age < 75 2.22 (1.34–3.29), .001
Gender .836
Female 2.05 (1.21–3.45),.007
Male 2.19 (1.51–3.17), <.001
Diagnosis
Infection 1.26 (0.62–2.58), .523 .095
Cardiovascular 3.91 (1.87–8.18), <.001 .102
Metabolic 0.53 (0.05–5.49), .597 .222
Cancer 2.18 (1.07–4.47), .033 .893
Neurological 2.10 (1.07–4.11), .031 .83
Gastrointestinal 0.49 (0.13–1.83), .290 .017
Pulmonary 1.92 (0.44–8.36), .383 .834
Other 5.79 (1.72–19.47), .005 .103
ICU admission Overall 1.62 (1.15–2.27), .005
Age, years .021
Age >75 0.76 (0.36–1.61), .475
Age <75 2.05 (1.40–3.02), <.001
Gender .765
Female 1.65 (0.89–3.05), .110
Male 1.47 (0.98–2.22), .064
Diagnosis
Infection 2.25 (0.76–6.67), .144 .582
Cardiovascular 2.22 (1.28–3.84), .005 .177
Metabolic 1.70 (0.10–28.70), .713 .973
Cancer Omitted
Neurological 0.49 (0.15–1.64), .249 .039
Gastrointestinal 3.60 (0.92–14.13), .066 .245
Pulmonary 0.97 (0.33–2.83), .959 .37
Other 1.27 (0.44–3.72), .656 .665
30-day readmission Overall 1.21 (0.96–1.52), .095
Age, years .654
Age >75 1.34 (0.83–2.15), .220
Age <75 1.19 (0.92–1.54), .193
Gender .623
Female 1.29 (0.89–1.86), .173
Male 1.15 (0.86–1.53), .345
Diagnosis
Infection 1.28 (0.70–2.35),.424 .88
Cardiovascular 1.70 (1.09–2.65),.019 .088
Metabolic 1.61 (0.32–8.17), .567 .731
(continued )





Outcome Monocytosis >0.8109/L OR (95% CI), P value P value for effect modiﬁcation
Cancer 0.95 (0.31–2.90), .926 .659
Neurological 0.71 (0.38–1.34), .293 .068
Gastrointestinal 2.03 (1.03–4.03), .042 .122
Pulmonary 1.08 (0.39–2.99), .887 .825
Other 0.95 (0.54–1.67), .853 .344
Functional impairment (Barthel <95) Overall 1.24 (1.01–1.53), .04
Age, years .117
Age >75 0.98 (0.73–1.33), .912
Age <75 1.39 (1.02–1.88), .036
Gender .249
Female 1.46 (1.07–2.01), .018
Male 1.14 (0.87–1.51), .340
Diagnosis
Infection 0.77 (0.48–1.24), .282 .048
Cardiovascular 1.47 (0.92–2.37), .111 .426
Metabolic 1.82 (0.11–31.03), .678 .791
Cancer 1.24 (0.51–3.02), .640 .986
Neurological 1.55 (1.02–2.36), .042 .451
Gastrointestinal 0.72 (0.35–1.48), .367 .105
Pulmonary 0.95 (0.38–2.38), .921 .574
Other 2.18 (1.24–3.83), .007 .033
Length of stay Overall 0.86 (0.79–0.94), .001
Age, years .079
Age >75 0.96 (0.82–1.12), .605
Age <75 0.82 (0.74–0.92), <.001
Gender .749
Female 0.87 (0.75–1.01), .063
Male 0.85 (0.76–0.95), .006
Diagnosis
Infection 0.94 (0.76–1.17), .587 .398
Cardiovascular 0.90 (0.75–1.09), .289 .591
Metabolic 0.64 (0.32–1.28), .211 .542
Cancer 0.86 (0.58–1.26), .426 .992
Neurological 0.76 (0.61–0.94), .012 .444
Gastrointestinal 0.78 (0.61–1.01), .055 .32
Pulmonary 0.90 (0.61–1.33), .603 .901
Other 0.86 (0.67–1.11), .254 .834
CI= conﬁdence interval, HR=hazard ratio, ICU= intensive care unit, OR=odds ratio.
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monocyte count group (Table 4).3.4. Functional impairment of patients
No differences were found in patients with monocytosis
regarding functional impairment in terms of mobility (P= .575),
usual activities (P= .256), self care (P= .879), pain or discomfort
(P= .366), or anxiety (P= .079) (Table 4).4. Discussion
Despite the profound knowledge in monocyte biology, surpris-
ingly little is known about monocytosis in the clinical setting. In
this large survey, we identiﬁed peripheral blood monocytosis as a
negative prognostic marker in the emergency setting. This is in
line with a plethora of previous studies showing that activation of
the innate immune system may be detrimentally associated with
critical illness.[18] Monocytes are a major source of oxidative
stress and thus can trigger organ damage under certain
circumstances.[19] Unfortunately, we could not specify the
monocyte subsets in this study. The role of the ‘inﬂammatory’5CD14 CD16 monocyte subset would be interesting and
important in order to understand the mechanism of monocytes
in critical illness.[20] Patients with monocytosis had more often
respiratory symptoms and suffered from infection than individu-
als with normal monocyte counts. In part this might be related to
the higher number of COPD patients in this group and indicates
that smoking, which was not assessed in this study, triggers
monocytosis. It can however be postulated that lung impairment,
most likely due to infection, is a main stimulator of monocytosis.
Fever, which was also associated with monocytosis in this study,
further indicates that a potentially unspeciﬁc systemic inﬂamma-
tory response is involved in monocytosis. Why neurologic
diagnosis inversely correlated with monocytosis is unclear and
surprising. Prior studies have shown an association between
monocytes and cerebral vascular disease.[16] Potentially, patrol-
ling monocytes at the inner side of the vessel wall behave
differently in blood–brain barrier than in the rest of the
circulation.
In contrast, cardiovascular diagnoses were the strongest
inﬂuence for the 30-day mortality in patients with monocytosis.
This is in line with previous studies showing that monocytosis is
also involved in the pathogenesis of atherosclerosis. Apart from
[2] Murray PJ, Wynn TA. Protective and pathogenic functions of
Table 4
Secondary outcomes baseline overall and according to monocyte count. OR/HR for primary outcomes in patients with a monocyte count
>0.8109/L compared to patientswith a normalmonocyte count. Adjusted for age /gender (Model 1), age/gender/comorbidities (Model 2),
and age/gender/comorbidities/main diagnosis (Model 3).
Overall
Monocytosis
>0.8109/L Unadjusted OR /
HR (95%CI), P value Model 1 Model 2 Model 3n 4238 1217
Functional impairment, n (%)
No functional impairment
(Barthel >95%)
3,448 (81.4%) 950 (78.1%)
Functional impairment
(Barthel <95%)
507 (12.0%) 158 (13.0%) 1.24 (1.01–1.53), .04 1.11 (0.89–1.38), .340 1.08 (0.87–1.36), .481 1.13 (0.89–1.42), .316
Barthel not assessed 283 (6.7%) 109 (9.0%)
Mobility, n (%)
No mobility limitation 1329 (31.4%) 405 (33.3%)
Mobility limitation 341 (8.1%) 98 (8.1%) 0.93 (0.71–1.21), .575 0.94 (0.72–1.23), .660 0.91 (0.69–1.19), .481 0.89 (0.67–1.19), .436
Mobility not assessed 2568 (60.6%) 714 (58.7%)
Usual activities, n (%)
No usual activities limitation 1211 (28.6%) 378 (31.1%)
Usual activities limitation 459 (10.8) 125 (24.9%) 0.87 (0.68–1.11), .256 0.91 (0.71–1.16), .439 0.88 (0.68–1.13), .314 0.89 (0.69–1.17), .409
Usual activities not assessed 2568 (60.6%) 125 (10.3%)
Self-care, n (%)
No self-care problems 1433 (33.8%) 431 (35.4%)
Self-care problems 237 (5.6%) 72 (5.9%) 1.02 (0.76–1.39), .879 1.04 (0.76–1.42), .828 1.01 (0.73–1.39), .972 0.99 (0.71–1.39), .952
Self-care not assessed 2568 (60.6%) 714 (58.7%)
Pain/discomfort, n (%)
No pain/discomfort 1121 (26.5%) 348 (28.6%)
Pain/discomfort 549 (13.0%) 155 (12.7%) 0.89 (0.72–1.13), .366 0.93 (0.74–1.18), .563 0.91 (0.72–1.15), .439 0.85 (0.67–1.08), .176
Pain/discomfort not assessed 2568 (60.6%) 714 (58.7%)
Anxiety/depression, n (%)
No anxiety/depression 1255 (29.6%) 394 (32.4%)
Anxiety/depression 415 (9.8%) 109 (9.0%) 0.79 (0.62–1.03), .079 0.84 (0.65–1.08), .180 0.83 (0.64–1.07), .153 0.87 (0.67–1.13), .300
Anxiety/depression not assessed 2568 (60.6%) 714 (58.7%)
EQ5D, n (%)
No EQ5D problems 834 (19.7%) 271 (22.3%)
EQ5D problems 1005 (23.7%) 287 (23.6%) 0.86 (0.71–1.06), .160 0.89 (0.72–1.09), .262 0.87 (0.70–1.07), .192 0.86 (0.69–1.07), .176
EQ5D not assessed 2399 (56.6%) 659 (54.1%)
VAS EQ5D, median (IQR) 80 (60, 90) 80 (60, 90)
CI= conﬁdence interval, HR=hazard ratio, IQR= interquartile range, OR= odds ratio, VAS = visual analog scale.
Hensel et al. Medicine (2017) 96:28 Medicinethe brain, we postulate thatmonocytosis is notably toxic to organs
affected from atherosclerosis, for example, by increased extrava-
sation or release of cytokines and oxidative stress.Monocytopenia
was also associated with an increased 30-mortality (data not
shown) in this survey but this mainly affected hematological
disorders and was not inﬂuenced by cardiovascular diagnoses.
Clearly, this study is observational and has several limitations. In
this survey we cannot draw conclusions about mechanistic
processes andwecannot answer thequestionwhethermonocytosis
is the cause or just a consequenceof adverseoutcome.Therewasno
negative effect of monocytosis on functional outcomes such as
mobility or pain. We therefore conclude that in case of
monocytosis, the activated innate immune system affects organ
function, notably in patients with an already impaired cardiovas-
cular system. Mechanistic studies are necessary in order to
understand the negative role of monocytosis in critical care and to
identify potential new treatment targets such as a monocyte-based
immune modulation in critical care.References
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